Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine the relative contributions of basal hyperglycemia (BHG) versus postprandial hyperglycemia (PPHG) before and after treatment intensification in patients with glycated hemoglobin A1c (A1C) >7.0% while on prior oral therapy. RESEARCH DESIGN AND METHODS: Self-measured, plasma-referenced glucose profiles and A1C values were evaluated from participants in six studies comparing systematically titrated insulin glargine with an alternative regimen (adding basal, premixed, or prandial insulin, or increasing oral agents). Hyperglycemic exposure (>100 mg/dL [5.6 mmol/L]) as a result of BHG versus PPHG was calculated. RESULTS: On prior oral therapy, 1,699 participants (mean age 59 years, diabetes duration 9 years) had mean fasting plasma glucose (FPG) of 194 mg/dL (10.8 mmol/L), and mean A1C was 8.7%. BHG contributed an average of 76–80% to hyperglycemia over the observed range of baseline A1C levels. Adding basal insulin for 24 or 28 weeks lowered mean FPG to 117 mg/dL (6.5 mmol/L), A1C to 7.0%, and BHG contribution to 32–41%. Alternative regimens reduced FPG to 146 mg/dL (8.1 mmol/L), A1C to 7.1%, and the contribution of BHG to 64–71%. BHG contributions for patients with A1C averaging 7.6–7.7% were 76% at baseline and 34 and 68% after adding basal insulin or other therapies, respectively. CONCLUSIONS: When A1C is >7.0% despite oral therapy, BHG routinely dominates exposure. Intensified therapy reduces A1C and changes this relationship, but BHG amenable to further intervention still accounts for one-third of total hyperglycemia after basal insulin treatment and two-thirds after alternative methods.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When A1C values are higher, the major contribution is the FPG levels, but as the A1C value approaches the target value of ≤7.0%, there is a greater contribution from PPG values (37-39).”
From Targets for Glycemic Control (2018) · cites this paper as [39]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Follow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s5 · Cited by 2,689
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461 · cited 3×
“89) AUCB (mg z h z dL (21)) Baseline 2,155 (1,176) 2,271 (1,183) 1,821 (1,091) 2,598 (1,220) 2,449 (1,256)”
BackgroundInfluentialMonnier, L., Colette, C., Dunseath, G. J., & Owens, D. R. (2007) · Diabetes Care · doi:10.2337/dc06-1612 · Cited by 490
Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study
Yki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Tulokas, T., Hulme, S., Hardy, K., McNulty, S., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0132-0 · Cited by 434
Janka, H. U., Plewe, G., Riddle, M. C., Kliebe-Frisch, C., Schweitzer, M. A., & Yki-Järvinen, H. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.254 · Cited by 414
Self-citation
Cited by
Items 101–200 of 225
Gupta, S., Puppalwar, P., & Chalak, A. (2014) · International Journal of Advances in Medicine · doi:10.5455/2349-3933.ijam20140824 · Cited by 13
Multidimensional effects of metformin in patients with type 2 diabetes
Ruyatkina, L. A., & Ruyatkin, D. S. (2017) · Diabetes Mellitus · doi:10.14341/dm2003458-64 · Cited by 16
Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy
Davidson, J. A. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1096743 · Cited by 12
Vijayakumar, V., Mavathur, R. N., Raguram, N., Ranjani, H., Anjana, R. M., & Mohan, V. (2021) · Journal of Diabetology · doi:10.4103/jod.jod_6_18 · Cited by 13
Raccah, D. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.82 · Cited by 13
Giorgino, F., Yu, M., Haupt, A., Milicevic, Z., & García-Pérez, L. (2019) · Diabetes, obesity and metabolism · doi:10.1111/dom.13844 · Cited by 11
Handelsman, Y., Muskiet, M. H. A., & Meneilly, G. S. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01126-x · Cited by 12
An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus
Novodvorský, P., & Haluzík, M. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1978974 · Cited by 13
Scheen, A. J., Schmitt, H., Jiang, H. H., & Iványi, T. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.10.005 · Cited by 11
Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes
Aronoff, S. L. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1285191 · Cited by 11
Gautier, T., Umpierrez, G. E., Renard, É., & Kovatchev, B. P. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819891170 · Cited by 11
Self-citationFeng, W., Wang, W., Meng, R., Wu, G., Zhang, M., Zhang, X., Yin, H., & Zhu, D. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002290 · Cited by 11
An overview of insulin therapy for the non‐specialist
Home, P. D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16280 · Cited by 13
Evidence-based clinical use of insulin premixtures
Tambascia, M. A., Nery, M., Gross, J. L., Ermetice, M. N., & de Oliveira, C. P. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-50 · Cited by 13
Lim, L., Brnabic, A. J., Chan, S. P., Ibrahim, L., Paramasivam, S. S., Ratnasingam, J., Vethakkan, S. R., & Tan, A. T. B. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12596 · Cited by 11
Acarbose versus Repaglinide in Diabetes Treatment: A New Appraisal of Two Old Rivals
Pishdad, R., Pishdad, P., & Pishdad, G. R. (2020) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2020.01.011 · Cited by 11
Yan, R., Hu, Y., Li, F.-F., Jiang, L., Xu, X., Wang, J., Zhang, Y., Ye, L., Lee, K., Su, X., et al. (2019) · International Journal of Endocrinology · doi:10.1155/2019/1267475 · Cited by 10
Ekanayake, P. S., & Edelman, S. V. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15059 · Cited by 10
Bitarafan, V., Anjom-Shoae, J., Rezaie, P., Fitzgerald, P. C. E., Lange, K. M., Horowitz, M., & Feinle‐Bisset, C. (2024) · Diabetologia · doi:10.1007/s00125-024-06344-9 · Cited by 11
Reznik, Y., Huang, S., & for the OpT2mise Study Group (2014) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0261 · Cited by 10
Margaritidis, C., Karlafti, E., Kotzakioulafi, E., Kantartzis, K., Τζιόμαλος, Κ., Kaiafa, G. D., Savopoulos, C. G., & Didangelos, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091982 · Cited by 9
Fasting Versus Postprandial Hyperglycemia as a Treatment Target to Lower Elevated Hemoglobin A1C
Shaefer, C. F., Reid, T., Vlajnic, A., Zhou, R., & DIGENIO, A. G. (2015) · Endocrine Practice · doi:10.4158/ep14498.or · Cited by 9
Self-citationUmpierrez, G. E., Pantalone, K. M., Atisso, C. M., Landó, L. F., & Patel, H. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13662 · Cited by 9
Self-citationSex Differences And Relationship Between Blood Pressure And Age Among The Ibos Of Nigeria
Warren, M. L. (2009) · The Internet Journal of Biological Anthropology · doi:10.5580/2cc · Cited by 9
Wang, J., Hung, Y.-J., Lu, Y.-C., Tsai, C.-L., Yang, W., Lee, T.-I., Hsiao, Y.-C., & Sheu, W. H. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.002 · Cited by 9
Strategies for implementing effective mealtime insulin therapy in type 2 diabetes
Peyrot, M. F., Bailey, T. S., Childs, B. P., & Reach, G. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1440200 · Cited by 10
Inzucchi, S. E., Umpierrez, G. E., DIGENIO, A. G., Zhou, R., & Kovatchev, B. P. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.09.002 · Cited by 9
Self-citationA time to revisit the two oldest prandial anti-diabetes agents: acarbose and repaglinide
Pishdad, P., Pishdad, R., Pishdad, G. R., & Panahi, Y. (2020) · Endocrine · doi:10.1007/s12020-020-02396-0 · Cited by 8
Methods to enhance delivery of prandial insulin and basal‐prandial insulin
Garber, A. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12067 · Cited by 8
Eto, K., Naito, Y., & Seino, Y. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0104-6 · Cited by 8
Roze, S., Smith‐Palmer, J., Delbaere, A., Bjornstrom, K., de Portu, S., Valentine, W. J., & Honkasalo, M. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0575-9 · Cited by 8
Reznik, Y., Habteab, A., Castañeda, J., Shin, J., & Joubert, M. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13398 · Cited by 8
2. Glycaemic control assessment and targets in type 2 diabetes
Colagiuri, S., & Ceriello, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112146 · Cited by 9
Yacoub, T. G. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2759 · Cited by 9
Yacoub, T. G. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1389601 · Cited by 7
Jordi, J., Herzog, B., Lutz, T. A., & Verrey, F. (2014) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00273.2014 · Cited by 7
Shi, L. X., Li, P. F., & Hou, J. N. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0286-z · Cited by 7
The prevalence and impact of low faecal elastase-1 in community-based patients with type 2 diabetes
Riceman, M. D., Bound, M. J., Grivell, J., Hatzinikolas, S., Piotto, S., Nguyen, N. Q., Jones, K. L., Horowitz, M., Rayner, C. K., & Phillips, L. K. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107822 · Cited by 7
Ling, P., Yang, D., Wang, C., Zheng, X., Luo, S., Yang, X., Deng, H., Xu, W., Yan, J., & Weng, J. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae291 · Cited by 6
Davidson, J. A., Stager, W., Paranjape, S., Berria, R., & Leiter, L. A. (2020) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-019-0088-5 · Cited by 6
Pabla, P., Mallinson, J. E., Nixon, A., Keeton, M., Cooper, S., Marshall, M. J., Jacques, M. F., Brown, S. A., Johansen, O. E., Cuenoud, B. M., et al. (2024) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.12.022 · Cited by 6
Møller, J. B., Kristensen, N. R., Klim, S., Karlsson, M., Ingwersen, S., & Kjellsson, M. (2014) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2014.20 · Cited by 6
Darmon, P., & Raccah, D. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30005-2 · Cited by 7
Terauchi, Y., Yabe, D., Kaneto, H., Amano, A., Baxter, M., Watanabe, D., Watada, H., & Inagaki, N. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14139 · Cited by 6
Ma, J., He, H., Yang, X., Chen, D., Tan, C., Zhong, L., Du, Q., Wu, X., Gao, Y., Liu, G., et al. (2021) · Nutrition and Diabetes · doi:10.1038/s41387-021-00156-1 · Cited by 7
YU, Y., YANG, J., & Tang, W. D. (2022) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.55730/1300-0144.5425 · Cited by 7
Martinez, Y. V., Campbell, S., Hann, M., & Bower, P. (2016) · Salud Pública de México · doi:10.21149/spm.v58i4.8020 · Cited by 6
Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus
Hanefeld, M., Raccah, D., & Monnier, L. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1251579 · Cited by 5
Liu, Y., Xu, H., Li, J., Yang, Y., Zhang, J., Liu, X., Li, J., Yu, Y., & Qin, G. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14826 · Cited by 5
Mata‐Cases, M. (2013) · Avances en Diabetología · doi:10.1016/j.avdiab.2013.07.002 · Cited by 5
John, M., Gopinath, D., & Oommen, T. (2020) · Dubai Diabetes and Endocrinology Journal · doi:10.1159/000509045 · Cited by 7
Younas, A., Riaz, J., Chughtai, T., Maqsood, H., Younus, S., Qasim, M. I., Saim, M., Qazi, S., Khaliq, M., & Fatima, M. (2021) · Cureus · doi:10.7759/cureus.13045 · Cited by 5
Fleming, G. A. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4920-0_12 · Cited by 5
Aronson, R. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.842465 · Cited by 5
Wang, X., Wu, G., Shen, D., Zhang, X., & Yang, W. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02128-y · Cited by 4
Calculadoras de bolus: mucho más que un glucómetro en el manejo de los pacientes con diabetes
Chico, A. I. (2013) · Avances en Diabetología · doi:10.1016/j.avdiab.2013.07.006 · Cited by 4
Molfetta, S. D., Laviola, L., Natalicchio, A., Leonardini, A., Cignarelli, A., Bonizzoni, E., Acmet, E., & Giorgino, F. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110836 · Cited by 4
Lin, S.-D., Su, S., Wang, S.-Y., Tu, S., & Hsu, S.-R. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.03.002 · Cited by 5
Bruhn, L., Vistisen, D., Vainø, C. T. R., Perreault, L., & Færch, K. (2020) · Endocrine · doi:10.1007/s12020-020-02234-3 · Cited by 4
Yabe, D., Iizuka, K., Baxter, M., Watanabe, D., & Kaneto, H. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13563 · Cited by 4
Uemura, F., Okada, Y., Torimoto, K., & Tanaka, Y. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0194 · Cited by 4
Shaefer, C. F., Reid, T., DIGENIO, A. G., Vlajnic, A., Zhou, R., Ameer, B., & Riddle, M. C. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2606 · Cited by 4
Self-citationVinagre, I., Sánchez-Hernández, J. J., Sánchez‐Quesada, J. L., María, M. A. M., de Leiva, A., & Pérez, A. (2013) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2012.11.007 · Cited by 4
Giorgino, F., Taybani, Z. J., CHENG, A. Y. Y., Tebaibia, A., Anaforoğlu, İ., Lauand, F., Servera, S., Li, X., & Fonseca, V. A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112945 · Cited by 3
Xiao, J., Wang, Q., Tan, S., Chen, L., Xiang, D., Yuan, H., Li, X., Huang, S., Tang, B., Guo, Y., et al. (2026) · Journal of Medical Internet Research · doi:10.2196/77470 · Cited by 3
Ju, H., Xu, X.-M., Shu, Z., Li, L., & Chen, Z.-J. (2014) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-014-0225-8 · Cited by 3
Chan, W. B., Luk, A. O. Y., Chow, W. S., & Yeung, M. W. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12515 · Cited by 4
Yuan, X., Li, D., Wang, K., Lauand, F., Zhang, M., Fang, H., Du, Q., Kang, L., Alvarez, A., & Guo, X. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15968 · Cited by 3
Hoey, H., Mlinac, A., Tran, C.-T., & Schlaeger, C. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0230 · Cited by 3
Riddle, M. C., Umpierrez, G. E., DIGENIO, A. G., Zhou, R., & Rosenstock, J. (2011) · Diabetes Care · doi:10.2337/dc11-1968 · Cited by 3
Self-citationFleischmann, H., Göke, R., & Bramlage, P. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.12.014 · Cited by 3
Targeting postprandial glycaemia in children with diabetes: O pportunities and challenges
Geyer, M. C., Rayner, C. K., Horowitz, M., & Couper, J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13141 · Cited by 5
Ma, J., Lei, M., Li, Y., Zhang, X., Cui, N., & Yang, W. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01410-1 · Cited by 3
Morin, N. P. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000003303 · Cited by 3
Glycemic Control in Switching Insulin-based Regimen Among Type 2 Diabetic Patients
Soewondo, P., & Subekti, I. (2012) · Journal Of The Indonesian Medical Association · Cited by 2
Zilov, A. V., & Болиева, Л. З. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-128 · Cited by 2
Wang, X., Bian, M., Li, F., Zhou, C., & Mu, L. (2026) · JMIR mhealth and uhealth · doi:10.2196/67410 · Cited by 2
Davidson, J. A., Desouza, C. V., Fonseca, V. A., Frías, J. P., Gaal, L. V., Giorgino, F., Chao, J., DEX, T. A., Roberts, M., Saremi, A., et al. (2019) · Diabetic Medicine · doi:10.1111/dme.14094 · Cited by 2
Aronson, R., Mahoney, E., Saliu, D., Sze, D., Morel, D. R., Bergquist, L., & Hirsch, L. J. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0356 · Cited by 2
Watson, L. E., Wu, T., Horowitz, M., & Rayner, C. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809868-4.00014-5 · Cited by 4
Akhtar, S., Wangnoo, S., Ghosal, S., Shetty, R., & Tripathi, S. (2014) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.139239 · Cited by 2
Berković, M. C., Mahečić, D. H., Gradišer, M., & Bilić-Čurčić, I. (2017) · Primary care diabetes · doi:10.1016/j.pcd.2017.02.004 · Cited by 2
On behalf of the Lantus Registry Study Group, Bu, S., Zhang, X., Zhu, H., Shuai, Y., Xing, X., & Yang, W. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0284-1 · Cited by 2
Li, W., Ping, F., Xu, L., Zhang, H., Dong, Y., Li, H., Sun, Q., & Li, Y. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0462-9 · Cited by 2
Austrian Experience with Lixisenatide Under Real-Life Conditions: A Prospective Observational Study
Brath, H., Abrahamian, H., Karuza, T., Mihaljevic, R., & Pfohl, M. (2019) · Diabetes Therapy · doi:10.1007/s13300-018-0558-2 · Cited by 2
Risk Factors for Preoperative Hyperglycemia in Surgical Patients with Diabetes: A Case–Control Study
Herk, P. V., Morin, N. P., Dersch‐Mills, D., Roedler, R. L., Ang, B., & Olivieri, L. (2022) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v75i1.3253 · Cited by 2
Yu, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70192 · Cited by 1
Block, C. E. M. D., Benamar, M., Fu, A., Maltesen, R., & Giorgino, F. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103985 · Cited by 1
Soto-González, A., & Bellido, D. (2013) · journal of Diabetes Research and Clinical Metabolism · doi:10.7243/2050-0866-2-20 · Cited by 1
Postprandial or Fasting Hyperglycemia: Time to Move On?
DeVries, J. H. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0158 · Cited by 1
Chandalia, H. B., & Thadani, P. (2016) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-016-0467-8 · Cited by 1
Ogiso, K., Koriyama, N., Obo, T., Tokito, A., & Nishio, Y. (2020) · Diabetology International · doi:10.1007/s13340-020-00457-3 · Cited by 1
Jones, K. L., Marathe, C. S., Wu, T., Rayner, C. K., & Horowitz, M. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-15613-7_27 · Cited by 1
Hwang, Y., Bok, M., Chon, S., & Lim, H. (2025) · Nutrition Research and Practice · doi:10.4162/nrp.2025.19.6.904 · Cited by 1
The Importance of Postprandial Hyperglycemia Position Statement of the Danube Mco Experts
Barkai, L., Hâncu, N., Jermendy, G., Konstantinova, M., Lichiardopol, R., Moța, M., Tankova, T. I., Temelkova, N., & Winkler, G. (2015) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.1515/rjdnmd-2015-0011 · Cited by 1
Peter, R., Dunseath, G. J., Luzio, S. D., & Owens, D. R. (2013) · Practical Diabetes · doi:10.1002/pdi.1735
Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine
Riddle, M. C., Forst, T. M., Aronson, R., Sauque‐Reyna, L., Souhami, E., Silvestre, L., Ping, L., & Rosenstock, J. (2013)
Self-citation(2013) · The Internet Journal of Family Practice · doi:10.5580/2ccf
Sultan, A. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30185-1
Metadata
- Authors
- Riddle, M., Umpierrez, G., DiGenio, A., Zhou, R., & Rosenstock, J.
- Affiliations
- Oregon Health & Science University (US)
- Emory University (US)
- Sanofi (United States) (US)
- Medpace (United States) (US)
- Dallas Diabetes and Endocrine Center, Dallas, Texas
- Corresponding author
- Riddle, Matthew
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-11-14
- Volume
- 34
- Issue
- 12
- Pages
- 2508-2514
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3220846
- OpenAlex
- W2103903409
- Cited by
- 219
- References
- 20
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 6 · 2023: 4 · 2022: 7 · 2021: 12 · 2020: 13 · 2019: 22 · 2018: 13 · 2017: 17 · 2016: 18 · 2015: 28 · 2014: 22 · 2013: 29 · 2012: 8
- FWCI
- 16.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Medpace
- MannKind Corporation
- European Foundation for the Study of Diabetes
- Novo Nordisk
- National Institutes of Health (UL1TR000454)
- National Center for Advancing Translational Sciences
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, postprandial hyperglycemia, HbA1c, treatment intensification, insulin glargine, basal insulin, oral antidiabetic drugs, fasting blood glucose, glycemic control
- MeSH terms
- Isophane Insulin, Human, Insulin Glargine, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Insulin, Isophane, Male, Middle Aged, Randomized Controlled Trials as Topic, Treatment Outcome, Insulin, Long-Acting, Insulin, Regular, Human
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.